ASX Healthcare Stocks in Focus: Strategic Alliances, Financial Updates and Expansion Plans

The following ASX listed firms have been making key moves through strategic alliances, business development, technology and financial strategies.

CSL Limited (ASX: CSL)

CSL Limited (ASX: CSL) on 29 June 2026, reported that the committee of the European Medicines Agency had proposed the revocation of the EU approval of TAVNEOS based on data from its phase 3 study. This matter will be decided by the European Commission in due course. In the meantime, CSL has decided to cease initiating patients on TAVNEOS in the EU/EEA markets. TAVNEOS is projected to bring in FY26 sales of about $145m.

On 11 May 2026, CSL issued revised FY26 guidance where the company expects its revenue to be at $15.2 billion and its NPATA to be at $3.1 billion using constant currency. The reasons behind the revised FY26 outlook are a decline in revenue for immunoglobulins, decreased pricing of albumin in China, effects of the Middle East war, slower growth of HEMGENIX and iron competition. The company is also anticipating non-cash impairment losses of around $5 billion in FY26 and FY27.

The business analysis revealed some progress in improving their operation, manufacturing, commercialization and cost-saving efforts with savings expected to reach $500 million to $550 million per annum by FY28.

ResMed Inc. (ASX: RMD)

ResMed Inc. (ASX: RMD) disclosed that it plans to divest the company’s MatrixCare division in a $490M cash deal with Frazier Healthcare Partners on 7 July 2026. This deal is anticipated to be completed by Q1 of FY2027. The company will use this money to expedite share repurchase and fund any other business needs. MatrixCare generated $220 million in revenues in FY2026.

On 1st May 2026, ResMed achieved sales of $1.4 billion in its third quarter representing a growth of 11% from last year's third quarter. An increase in demand for sleep products, masks and accessories was the reason behind good results. Gross margin increased to 62.2%, operating income improved by 17% and diluted EPS was $2.74. Operating cash flow was $554 million, with $262 million being returned to the shareholders.

Moreover, RMD is planning to open a new distribution center in the United States in 2027, introduced AirTouch F30i Comfort mask in the US and conducted a Global Sleep Survey in 13 countries.

Pro Medicus (ASX: PME)

The Company announced on 25 June 2026 a legally binding Heads of Agreement with Echo IQ in relation to a finance facility and reseller agreement. The terms include a strategic investment in the range of A$20 million for the development and commercialization of Echo IQ's AI technologies for the treatment of aortic stenosis and heart failure. Additionally, Pro Medicus may be able to provide its Echo IQ technologies to Visage 7 Cardiology customers in the USA.

Pro Medicus extended its contract worth A$16 million for 5 years with The Ohio State University Wexner Medical Center on 4 June 2026. The deal comprises Visage 7 Workflow and Visage 7 Cardiology Imaging along with a transaction-based payment structure and more stringent minimum obligations.

Pro Medicus declared that FY26 financial results would be declared on 18 August 2026. PME is still concentrating on medical imaging software development and advancing their AI approach.

( Source : Market Analysis )